Health Condition 1: null- Indian participants with Rheumatoid Arthritis will be enrolled in the study
Conditions
Interventions
Intervention1: NIL: This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed Simponi�® as per in
Sponsors
Johnson Johnson Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Participants of rheumatoid arthritis (RA), who are being prescribed and initiated on golimumab as per independent clinical judgment of treating Physicians based on the locally approved Prescribing Information Participants must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and willing to participate in the study
Exclusion criteria
Exclusion criteria: Participants participating or planning to participate in any interventional drug trial during the course of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and drug related AEs Percentage of participants with Infections and Serious InfectionsTimepoint: Up to 8 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Following parameters associated with usage of SimponiÃ?® (golimumab, 50 mg SC injection) 1. Baseline subject and disease characteristics 2. Progression of disease 3. Change in subject reported outcomes HAQ-DI, FACIT-F, Satisfaction and user-friendliness of autoinjector, Pain and other reactions at injection site, Actual timing of golimumab dose interval, methotrexate dose (mg per week) and folic acid (mg per week)Timepoint: Up to 8 months | — |
Countries
India
Contacts
Public ContactDr Jitendra R Dixit
Johnson and Johnson Private Limited
Outcome results
None listed